| human | Q5 |
| P691 | NL CR AUT ID | jo20000074063 |
| P496 | ORCID iD | 0000-0002-5247-7746 |
| P3829 | Publons author ID | 2058922 |
| P1053 | ResearcherID | O-1817-2017 |
| P1153 | Scopus author ID | 55448533100 |
| P214 | VIAF ID | 84111332 |
| P1343 | described by source | Medvik | Q99413897 |
| Records of persons of interest | Q104900509 | ||
| P108 | employer | Charles University | Q31519 |
| P734 | family name | Roth | Q2168571 |
| Roth | Q2168571 | ||
| Roth | Q2168571 | ||
| P735 | given name | Jan | Q12173670 |
| Jan | Q12173670 | ||
| P106 | occupation | researcher | Q1650915 |
| neurologist | Q783906 | ||
| P21 | sex or gender | male | Q6581097 |
| Q122081987 | Neuropsychiatrie: klinický průvodce pro ambulantní i nemocniční praxi |
| Q45303161 | A sensitivity comparison of clinical tests for postural instability in patients with Huntington's disease |
| Q83836549 | Acoustic assessment of voice and speech disorders in Parkinson's disease through quick vocal test |
| Q64764138 | Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease |
| Q45302071 | Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. |
| Q45303696 | Auditory dysfunction in patients with Huntington's disease |
| Q82821015 | Beneficial effect of deep brain stimulation of GPi in a patient with dystonia-deafness phenotype |
| Q46718369 | Changes of hand preference in Parkinson's disease. |
| Q35097665 | Changes of retina are not involved in the genesis of visual hallucinations in Parkinson's disease |
| Q45299193 | Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication |
| Q62844764 | Clinical and genetic characteristics of late-onset Huntington's disease |
| Q30912738 | Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson's disease and normative data. |
| Q39678673 | Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up |
| Q77391777 | Colour discrimination impairment is not a reliable early marker of Parkinson's disease |
| Q35185903 | Correlation between relaxometry and diffusion tensor imaging in the globus pallidus of Huntington's disease patients |
| Q48628017 | Deep brain stimulation of the subthalamic nucleus affects resting EEG and visual evoked potentials in Parkinson's disease |
| Q47870612 | Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease |
| Q45304062 | Disturbance of real space navigation in moderately advanced but not in early Huntington's disease. |
| Q84571636 | Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease? |
| Q50607834 | Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study. |
| Q42957249 | Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. |
| Q74107584 | Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-contr |
| Q46137935 | Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy. |
| Q34035394 | Eye movements in ephedrone-induced parkinsonism |
| Q37685823 | Frequency-phase analysis of resting-state functional MRI. |
| Q38675271 | Frontal Assessment Battery in Parkinson's Disease: Validity and Morphological Correlates. |
| Q77365092 | Functional magnetic resonance imaging during deep brain stimulation: a pilot study in four patients with Parkinson's disease |
| Q50927521 | GABA spectra and remote distractor effect in progressive supranuclear palsy: A pilot study. |
| Q51822518 | Handedness does not predict side of onset of motor symptoms in Parkinson's disease. |
| Q46396481 | Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion |
| Q45296789 | Importance of psychiatric examination in predictive genetic testing for Huntington disease |
| Q46265216 | Imprecise vowel articulation as a potential early marker of Parkinson's disease: effect of speaking task |
| Q62977311 | Impulse control disorders in patients with young-onset Parkinson’s disease: A cross-sectional study seeking associated factors |
| Q83198099 | Influence of emotional instability on behavioral disorders in DYT11 |
| Q48648413 | KMT2B rare missense variants in generalized dystonia |
| Q43679755 | Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. |
| Q45305485 | MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. |
| Q52655579 | Mild cognitive impairment disrupts attention network connectivity in Parkinson's disease: A combined multimodal MRI and meta-analytical study. |
| Q47711036 | Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing. |
| Q39160382 | Motion and emotion: anxiety-axial connections in Parkinson's disease |
| Q30453596 | Objective acoustic quantification of phonatory dysfunction in Huntington's disease |
| Q34215600 | Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease |
| Q33762389 | Physiotherapy in Parkinson's Disease: Building ParkinsonNet in Czechia |
| Q35800721 | Predicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State? |
| Q41954797 | Separate neural representations of depression, anxiety and apathy in Parkinson's disease. |
| Q44499646 | Sleep disturbances in untreated Parkinson's disease. |
| Q47291758 | Spinocerebellar ataxias type 8, 12, and 17 and dentatorubro-pallidoluysian atrophy in Czech ataxic patients |
| Q48526323 | Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics |
| Q92582895 | The Diagnostic Accuracy of Parkinson's Disease Mild Cognitive Impairment Battery Using the Movement Disorder Society Task Force Criteria |
| Q81300045 | The McLeod syndrome without acanthocytes |
| Q39151379 | The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. |
| Q45301737 | The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease |
| Q45293843 | The relationship between impairment of voluntary movements and cognitive impairment in Huntington's disease. |
| Q48176399 | VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy |
| Q45291627 | Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease |
| Q45305450 | Variation of selective gray and white matter atrophy in Huntington's disease |
Search more.